An archive and transcript of this call will be available on the Regeneron Investor Relations website shortly after ... primarily, Dupixent, Libtayo, and EYLEA and EYLEA HD. 2024 was also a year ...

The sale of Sanofi's controlling stake in consumer health business Opella is expected to close in the second quarter at the earliest, completing its transition into a pure-play drug and vaccine ...

French drugmaker Sanofi reported a fourth-quarter profit that came in-line with analysts' estimates on Thursday, and said it would buy back 5 billion euros ($5.21 billion) in shares this year as it ...

All the necessary information is either in 20-Fs/10-Ks or on the FDA website, namely in the "Orange ... So, sales of Dupixent (dupilumab), an IL-4/IL-13 inhibitor, in the third quarter of 2024 ...

Regeneron Pharmaceuticals beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema ...

Sanofi and Regeneron have celebrated a pair of positive clinical trials in inflammatory skin disorders with blockbuster immunology therapy Dupixent that could both lead to new indications for the ...

The success of dupilumab, marketed by Sanofi under the name Dupixent, is evident in its remarkable $13 billion global sales achievement in 2024, marking a significant milestone for the company.

The CEO discussed the success of Dupixent and the remarkable achievement of over $13 billion in global sales in 2024, highlighting its commercial advantage and setting a milestone for Sanofi.

Dupixent (dupilumab) was the first biologic medicine to get approval for atopic dermatitis in 2017, and since then has grown sales to more than $2 billion last year, with Sanofi suggesting it ...

One primary reason is the strong performance and potential of Dupixent, which is expected to partially counterbalance the uncertainties surrounding Eylea. The expected growth in Dupixent’s ...

Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting that it has reached over $13bn in global sales, which affirms its commercial advantage and sets a milestone ...